Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with ...

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients ...

Adam was told he had reached the end of the line in treatment and to prepare for a final Christmas with his wife and three ...

The main character 'Gwansik' in the recently popular Netflix drama 'I've been tricked' has died of multiple myeloma, making ...

Adam Nicolson, 55, was told in summer 2023 that he had reached the end of the line in his cancer treatment and to prepare to ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...